Sun Pharma’s research arm, SPARC, is tightening its belt and turning its focus toward high‑potential cancer and immune‑system medicines, aiming to save about $10 million each year.
Cost‑cutting and debt management
SPARC is shrinking its operations to stretch cash:
- U.S. staff cut by more than 80%.
- Laboratories reduced from four sites to two.
- Total headcount dropping from 409 in FY24 to about 246 by FY27.
- R&D budget lowered to $14.3 million for FY25 (down from $20.4 million).
- Targeting $10 million in annual cost savings while managing $46 million of debt.
Portfolio pivot to oncology and immunology
The company is moving away from lower‑priority projects and concentrating on a smaller set of promising drugs:
- De‑prioritising Vodobatinib, a drug for chronic myeloid leukaemia.
- Focusing on high‑value assets in cancer treatment and immune‑related skin conditions.
- Using a mix of in‑house work and outsourced partners to keep costs low.
Key pipeline highlights
SBO‑154 – an antibody‑drug conjugate targeting the MUC1‑SEA protein, now in Phase 1a dose‑escalation trials for lung, breast, ovarian and pancreatic cancers. The next dose‑finding readout is expected by the end of 2026.
SCD‑153 – a first‑in‑class topical drug for hair loss (alopecia areata) developed with Johns Hopkins University. Phase 1b safety data are complete, with larger studies for alopecia and vitiligo planned for 2026.
Future catalysts
- Outcome of a PRV voucher appeal (Q1 2026).
- Result of the NDA resubmission for PDP‑716 (Q1 2026).
- License agreement with the new company Tiller Therapeutics.
- Phase 1b readouts for SCD‑153 and other early‑stage programs.
What this means for investors
By cutting expenses and sharpening its drug focus, SPARC hopes to extend its cash runway through FY27‑28 and improve the chance of delivering market‑moving data. The streamlined portfolio could make the company more attractive for future partnerships or a possible sale.
Remember, this is perspective, not prediction. Do your own research and consider your risk tolerance before making any investment decisions.